TWI419681B - 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 - Google Patents

胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 Download PDF

Info

Publication number
TWI419681B
TWI419681B TW095120134A TW95120134A TWI419681B TW I419681 B TWI419681 B TW I419681B TW 095120134 A TW095120134 A TW 095120134A TW 95120134 A TW95120134 A TW 95120134A TW I419681 B TWI419681 B TW I419681B
Authority
TW
Taiwan
Prior art keywords
sleep
mirror image
formula
compound
eds
Prior art date
Application number
TW095120134A
Other languages
English (en)
Chinese (zh)
Other versions
TW200716084A (en
Inventor
艾達 安
卓威翰
白喬瑟
施強生
Original Assignee
Ｓｋ生物製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI419681(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ｓｋ生物製藥股份有限公司 filed Critical Ｓｋ生物製藥股份有限公司
Publication of TW200716084A publication Critical patent/TW200716084A/zh
Application granted granted Critical
Publication of TWI419681B publication Critical patent/TWI419681B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW095120134A 2005-06-08 2006-06-07 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途 TWI419681B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08

Publications (2)

Publication Number Publication Date
TW200716084A TW200716084A (en) 2007-05-01
TWI419681B true TWI419681B (zh) 2013-12-21

Family

ID=37085728

Family Applications (2)

Application Number Title Priority Date Filing Date
TW101130937A TW201328689A (zh) 2005-06-08 2006-06-07 治療睡眠-覺醒病症之方法
TW095120134A TWI419681B (zh) 2005-06-08 2006-06-07 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW101130937A TW201328689A (zh) 2005-06-08 2006-06-07 治療睡眠-覺醒病症之方法

Country Status (17)

Country Link
US (8) US8440715B2 (enExample)
EP (1) EP1890684B1 (enExample)
JP (1) JP5024635B2 (enExample)
KR (1) KR101335941B1 (enExample)
CN (1) CN101217949B (enExample)
AU (1) AU2006254899B2 (enExample)
BE (1) BE2020C004I2 (enExample)
BR (1) BRPI0613697A2 (enExample)
CA (1) CA2611713C (enExample)
DK (1) DK1890684T3 (enExample)
ES (1) ES2435403T3 (enExample)
FR (1) FR20C1014I2 (enExample)
NL (1) NL301037I2 (enExample)
PL (1) PL1890684T3 (enExample)
RU (1) RU2417077C2 (enExample)
TW (2) TW201328689A (enExample)
WO (1) WO2006133393A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2435403T3 (es) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
US8552060B2 (en) * 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496228B1 (en) * 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии
EP3021838B1 (en) 2013-07-18 2020-05-27 Jazz Pharmaceuticals Ireland Limited Treatment for obesity
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) * 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (en) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Amine reuptake inhibitors
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
WO2018048871A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CA3039045A1 (en) 2016-10-06 2018-04-12 Jazz Pharmaceuticals International Iii Limited Carbamoyl phenylalaninol compounds and uses thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
CN111094238B (zh) * 2017-07-31 2023-06-09 杰资制药爱尔兰有限公司 氨基甲酰基苯丙氨醇类似物及其用途
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
EP4615426A1 (en) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions and methods for treating insomnia
EP4626417A1 (en) * 2022-11-30 2025-10-08 Axsome Therapeutics Methods and compositions for improving driving performance
CN121620365A (zh) 2023-06-29 2026-03-06 艾克萨姆治疗股份有限公司 向哺乳期妇女施用索安非托的方法
WO2025165760A1 (en) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phenylalkylamino carbamates for use in the treatment of attention deficit/hyperactivity disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756817A (en) * 1995-02-11 1998-05-26 Yukong Limited O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
US5955499A (en) * 1994-09-09 1999-09-21 Yukong Limited Phenylalkylaminoalcohol carbamates and process for preparing the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR0173862B1 (ko) * 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) * 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
MXPA03007720A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.
CN1262272C (zh) 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
CA2439475C (en) 2001-02-27 2010-05-18 Carlos R. Plata-Salaman Carbamate compounds for use in preventing or treating bipolar disorder
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
RU2007119648A (ru) 2004-10-28 2008-12-10 СК Холдингз Ко. Способ лечения депрессии
ES2435403T3 (es) * 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Tratamiento de trastornos del sueño y vigilia
US8552060B2 (en) 2005-06-22 2013-10-08 Sk Biopharmaceuticals Co., Ltd. Methods for treatment of sexual dysfunction
CA2616721C (en) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Methods for treating substance-related disorders
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
US8741950B2 (en) 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783633B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 섬유근육통 증후군의 치료 방법
EP2496228B1 (en) 2009-11-06 2014-01-15 SK Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
RU2689984C2 (ru) * 2013-03-13 2019-05-30 ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи Лечение катаплексии

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955499A (en) * 1994-09-09 1999-09-21 Yukong Limited Phenylalkylaminoalcohol carbamates and process for preparing the same
US5756817A (en) * 1995-02-11 1998-05-26 Yukong Limited O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Black JE, et al. "Narcolepsy and syndromes of primary excessive daytime somnolence" Seminars in Neurology 2004; 24(3):271-282. *

Also Published As

Publication number Publication date
TW200716084A (en) 2007-05-01
US20190367448A1 (en) 2019-12-05
RU2008100019A (ru) 2009-07-20
US20140350098A1 (en) 2014-11-27
US10351517B2 (en) 2019-07-16
US20130137764A1 (en) 2013-05-30
NL301037I2 (nl) 2020-05-12
AU2006254899B2 (en) 2011-11-24
US8440715B2 (en) 2013-05-14
US12209059B2 (en) 2025-01-28
EP1890684A1 (en) 2008-02-27
US8877806B2 (en) 2014-11-04
ES2435403T3 (es) 2013-12-19
DK1890684T3 (da) 2013-10-14
BRPI0613697A2 (pt) 2011-01-25
KR20080035565A (ko) 2008-04-23
FR20C1014I2 (fr) 2021-04-23
US20250109099A1 (en) 2025-04-03
US11753368B2 (en) 2023-09-12
EP1890684B1 (en) 2013-08-14
RU2417077C2 (ru) 2011-04-27
KR101335941B1 (ko) 2013-12-04
PL1890684T3 (pl) 2014-05-30
JP2008545795A (ja) 2008-12-18
CA2611713A1 (en) 2006-12-14
CN101217949B (zh) 2012-10-17
FR20C1014I1 (enExample) 2020-06-12
TW201328689A (zh) 2013-07-16
CN101217949A (zh) 2008-07-09
US9604917B2 (en) 2017-03-28
JP5024635B2 (ja) 2012-09-12
US20170158622A1 (en) 2017-06-08
CA2611713C (en) 2013-10-01
WO2006133393A1 (en) 2006-12-14
US20090312416A1 (en) 2009-12-17
NL301037I1 (enExample) 2020-04-01
US20240239740A1 (en) 2024-07-18
BE2020C004I2 (enExample) 2026-01-06
AU2006254899A1 (en) 2006-12-14
US20210078943A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
TWI419681B (zh) 胺基甲酸酯用於製造供治療白天過度嗜睡（eds）的藥物之用途
JP5901528B2 (ja) 線維筋痛症候群の治療方法
CA2609612C (en) Use of huperzine to treat epilepsy
TW201103531A (en) Compositions for treating drug addiction and improving addiction-related behavior
PT2701693T (pt) Tapentadol para prevenção e tratamento de depressão e ansiedade
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
JP5271473B2 (ja) 神経障害性疼痛ならびに群発性頭痛および偏頭痛に関連する疼痛の予防もしくは治療における使用のためのカルバメート化合物
JP5017268B2 (ja) 覚醒を改善する方法
JP2010533717A (ja) 覚醒を促進する方法
JP4362367B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
JP2005314347A (ja) 疼痛抑制剤
JP4362368B2 (ja) 神経因性疼痛および群発および偏頭痛に伴う疼痛の防止または処置に使用するためのカルバメート化合物
US20250064802A1 (en) Methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases